August 2023: The fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), along with prednisone, has been approved by the Food and Drug Administration for adult pa...
brca-mutated-prostate-cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspecte...
brca-mutated-prostate-cancer